BR112012018343A2 - "composições imunogênicas" - Google Patents

"composições imunogênicas"

Info

Publication number
BR112012018343A2
BR112012018343A2 BR112012018343A BR112012018343A BR112012018343A2 BR 112012018343 A2 BR112012018343 A2 BR 112012018343A2 BR 112012018343 A BR112012018343 A BR 112012018343A BR 112012018343 A BR112012018343 A BR 112012018343A BR 112012018343 A2 BR112012018343 A2 BR 112012018343A2
Authority
BR
Brazil
Prior art keywords
pneumoniae
immunogenic
immunogenic compositions
compositions
isolated
Prior art date
Application number
BR112012018343A
Other languages
English (en)
Inventor
Ljutic Belma
Ausar Fernando
Morefield Garry
Harper Kevin
Danielle Salha Marie
Ochs Ochs Martina
Gallichan Scott
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Publication of BR112012018343A2 publication Critical patent/BR112012018343A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

composições imunogênicas. esta revelação diz respeito às composições imunogênicas compreendendo um polipeptídeo de pcpa de s. pneumoniae imunogênico isolado e pelo menos um antígeno adicional (tal como por exemplo, um polipeptídeo de s. pneumoniae imunogênico isolado selecionado do grupo que consiste na família de proteínas da tríade de poli-histidina (por exemplo, phtd) e métodos de usar estas composições para prevenir e tratar doenças causadas por s. pneumoniae.
BR112012018343A 2009-12-22 2010-12-20 "composições imunogênicas" BR112012018343A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28923609P 2009-12-22 2009-12-22
US32566010P 2010-04-19 2010-04-19
PCT/CA2010/001977 WO2011075823A1 (en) 2009-12-22 2010-12-20 Immunogenic compositions

Publications (1)

Publication Number Publication Date
BR112012018343A2 true BR112012018343A2 (pt) 2017-06-27

Family

ID=44194860

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012018343A BR112012018343A2 (pt) 2009-12-22 2010-12-20 "composições imunogênicas"

Country Status (12)

Country Link
US (1) US20130183350A1 (pt)
EP (1) EP2515938A4 (pt)
JP (2) JP5894083B2 (pt)
KR (1) KR20120107121A (pt)
CN (1) CN102802664B (pt)
AR (1) AR079712A1 (pt)
AU (1) AU2010335970B2 (pt)
BR (1) BR112012018343A2 (pt)
CA (1) CA2783955A1 (pt)
IL (2) IL220576B (pt)
WO (1) WO2011075823A1 (pt)
ZA (1) ZA201204628B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2515940A4 (en) 2009-12-22 2013-10-09 Sanofi Pasteur Ltd IMMUNOGENIC COMPOSITIONS AND CORRESPONDING METHODS
WO2012075428A1 (en) 2010-12-03 2012-06-07 Sanofi Pasteur Limited Composition for immunization against streptococcus pneumoniae
US20140072622A1 (en) 2011-05-17 2014-03-13 Glaxosmithkline Biologicals S.A. Vaccine against streptococcus pneumoniae
KR20150072444A (ko) * 2012-10-17 2015-06-29 글락소스미스클라인 바이오로지칼즈 에스.에이. 하나 이상의 스트렙토코커스 뉴모니애 캡슐 사카라이드 컨쥬게이트 및 해모필루스 인플루엔자로부터의 단백질 Ｅ 및／또는 ＰｉｌＡ를 포함하는 단백질 성분을 포함하는 면역원성 조성물
GB201218660D0 (en) 2012-10-17 2012-11-28 Glaxosmithkline Biolog Sa Immunogenic composition
WO2014089706A1 (en) * 2012-12-14 2014-06-19 Sanofi Pasteur, Ltd. Methods for assessing immunogenicity
CA2941826A1 (en) * 2014-03-10 2015-09-17 Sanofi Pasteur Limited Immunogenic compositions
KR101688960B1 (ko) * 2014-06-11 2016-12-23 전남대학교산학협력단 스쿠티카충 백신 조성물
EP3250228A1 (en) * 2015-01-27 2017-12-06 3M Innovative Properties Company Alum-containing coating formulations for microneedle vaccine patches
WO2017007835A1 (en) * 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for nanoemulsion vaccine formulations
EP3736574A1 (en) * 2019-05-07 2020-11-11 Atlas Antibodies AB A formulation comprising an isotope labeled fusion polypeptide
WO2023034932A1 (en) * 2021-09-02 2023-03-09 Vaxcyte, Inc. Stabilization of adjuvanted vaccine compositions and their use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3237842B2 (ja) * 1988-12-16 2001-12-10 オランダ国 ニューモリシンミュータント及びそれから製造されたニューモコッカルワクチン
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
JP4689044B2 (ja) * 1998-12-21 2011-05-25 メディミューン，インコーポレーテッド ワクチン用の肺炎連鎖球菌タンパク質と免疫原断片
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
GB0213622D0 (en) * 2002-06-13 2002-07-24 Glaxosmithkline Biolog Sa Vaccine Corporation
GB0410220D0 (en) * 2004-05-07 2004-06-09 Kirkham Lea Ann Mutant pneumolysin proteins
JP5869744B2 (ja) * 2005-03-23 2016-02-24 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム Ｃｄ４ｔ細胞および／または改善された記憶ｂ細胞応答を誘導するためのインフルエンザウイルスおよび水中油型エマルジョンアジュバントの使用
TWI457133B (zh) * 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
WO2008022298A2 (en) 2006-08-17 2008-02-21 The Uab Research Foundation Immunogenic pcpa polypeptides and uses thereof
AU2008280799B2 (en) 2007-07-23 2013-07-11 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
EP2235531B1 (en) * 2008-02-01 2015-01-14 Sanofi Pasteur Limited Assay for diagnosing streptococcus pneumoniae
EP2376526A4 (en) * 2008-12-24 2013-02-27 Kingdom Of The Netherlands Represented By The Min Ister Of Health Welfare & Sport On Behalf Of The M MODIFIED STREPTOCOCCUS PNEUMONIAE PNEUMOLYSIN (PLY) POLYPEPTIDE

Also Published As

Publication number Publication date
IL242592A (en) 2017-10-31
IL220576B (en) 2018-03-29
ZA201204628B (en) 2013-02-27
AR079712A1 (es) 2012-02-15
JP2013515015A (ja) 2013-05-02
CN102802664B (zh) 2017-04-05
AU2010335970B2 (en) 2016-11-03
JP5894083B2 (ja) 2016-03-23
AU2010335970A1 (en) 2012-07-05
KR20120107121A (ko) 2012-09-28
CA2783955A1 (en) 2011-06-30
US20130183350A1 (en) 2013-07-18
WO2011075823A1 (en) 2011-06-30
CN102802664A (zh) 2012-11-28
EP2515938A1 (en) 2012-10-31
JP2016104776A (ja) 2016-06-09
EP2515938A4 (en) 2013-08-28

Similar Documents

Publication Publication Date Title
BR112012018343A2 (pt) "composições imunogênicas"
GT201400097A (es) Agentes de iarn, composiciones y métodos de uso de los mismos para tratar enfermedades asociadas con transtiretina (ttr)
BR112017002221A2 (pt) 2-(morfolin-4-il)-1,7-naftiridinas
BR112014006822A2 (pt) proteínas de ligação ao antígeno cd27l
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
BR112012012918A8 (pt) Agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes
BRPI0922220A8 (pt) Uso de compostos antibacterianos, composição farmacêutica e combinação compreendendo os mesmos
GT201200172A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes
CO6551721A2 (es) Moduladores de cinasa novedosos
GT201200258A (es) Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf)
HN2012000798A (es) Derivados de glicosidos y usos de los mismos.
BR112013028907A2 (pt) conjugados de proteína-agente ativo e método para preparar os mesmos
EA201001639A1 (ru) Композиции и способы их получения и применения
BR112012005713A2 (pt) vacinas direcionadas a célula langerhans.
CR11313A (es) Composiciones y metodos de uso para anticuerpos contra la esclerostina
BR112012021652A2 (pt) composto, uso do mesmo, e, composição farmacêutica
UY30572A1 (es) N-(1-ftalazin-1-il-piperidin-4-il)-amidas como moduladores del receptor ep2
UY30220A1 (es) Compuestos de tetrahidropiridotienopirimidina y metodos para su empleo
BR112015021483A2 (pt) arginina deiminase com reduzida reatividade cruzada para anticorpos adi-peg 20 para o tratamento do câncer
BR112017015789A2 (pt) vacina de vírus da influenza suína bivalente
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
BR112018014540A2 (pt) formulações/composições compreendendo inibidor de btk
BR112014025968A2 (pt) composição e processo para o recurtimento e engraxe de couro, e couro preparado
ECSP21003171A (es) Dinucleótidos cíclicos como agonistas de sting
SV2005002015A (es) Procesos para la preparacion de haluros de aril- y heteroaril-alquilsulfonilo - ref. wyth0008-504 (am101302)

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 9A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2545 DE 15-10-2019 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.